Dose-dense temozolomide regimens: antitumor activity, toxicity, and immunomodulatory effects (Q37766550)

22 August 2017

1 reference

title

Dose-dense temozolomide regimens: antitumor activity, toxicity, and immunomodulatory effects (English)

1 reference

22 August 2017

0 references

4

David A Reardon

1 reference

22 August 2017

Bart Neyns

1

1 reference

22 August 2017

Alicia Tosoni

series ordinal

2

1 reference

22 August 2017

Wen-Jen Hwu

series ordinal

3

1 reference

22 August 2017

language of work or name

English

0 references

publication date

1 June 2010

1 reference

22 August 2017

1 reference

22 August 2017

116

1 reference

22 August 2017

12

1 reference

22 August 2017

2868-2877

1 reference

Differential radiosensitizing potential of temozolomide in MGMT promoter methylated glioblastoma multiforme cell lines.

22 August 2017

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25035

Molecular heterogeneity of oligodendrogliomas suggests alternative pathways in tumor progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25035

O6-methylguanine-DNA methyltransferase in pretreatment tumour biopsies as a predictor of response to temozolomide in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25035

CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25035

Multicentre CRC phase II trial of temozolomide in recurrent or progressive high-grade glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25035

7 January 2021

Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25035

7 January 2021

Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25035

7 January 2021

The Charing Cross Hospital experience with temozolomide in patients with gliomas.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25035

7 January 2021

A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25035

7 January 2021

Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25035

7 January 2021

Temozolomide in the treatment of recurrent malignant glioma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25035

7 January 2021

Temozolomide for the treatment of recurrent supratentorial glioma: results of a compassionate use program in Belgium

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25035

7 January 2021

Clinical relevance of MGMT in the treatment of cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25035

7 January 2021

Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25035

7 January 2021

MGMT gene silencing and benefit from temozolomide in glioblastoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25035

7 January 2021

Phase II trial of lomustine plus temozolomide chemotherapy in addition to radiotherapy in newly diagnosed glioblastoma: UKT-03.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25035

7 January 2021

MGMT promoter hypermethylation correlates with a survival benefit from temozolomide in patients with recurrent anaplastic astrocytoma but not glioblastoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25035

7 January 2021

Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25035

7 January 2021

Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25035

7 January 2021

Temozolomide-mediated radiosensitization of human glioma cells in a zebrafish embryonic system

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25035

7 January 2021

In vitro and in vivo radiosensitization induced by the DNA methylating agent temozolomide

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25035

7 January 2021

The anti-angiogenic basis of metronomic chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25035

7 January 2021

The anti-tumour effect of low-dose continuous chemotherapy may partly be mediated by thrombospondin

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25035

7 January 2021

Modulation of the antitumor activity of metronomic cyclophosphamide by the angiogenesis inhibitor axitinib

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25035

7 January 2021

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25035

7 January 2021

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25035

7 January 2021

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25035

7 January 2021

Temozolomide rechallenge in recurrent malignant glioma by using a continuous temozolomide schedule: the "rescue" approach

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25035

7 January 2021

Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25035

7 January 2021

Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO).

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25035

7 January 2021

A phase II study of extended low-dose temozolomide in recurrent malignant gliomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25035

7 January 2021

A multicenter cohort study of dose-dense temozolomide (21 of 28 days) for the treatment of recurrent anaplastic astrocytoma or oligoastrocytoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25035

7 January 2021

Dose-dense regimen of temozolomide given every other week in patients with primary central nervous system tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25035

7 January 2021

New (alternative) temozolomide regimens for the treatment of glioma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25035

7 January 2021

Phase II study of primary temozolomide chemotherapy in patients with WHO grade II gliomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25035

7 January 2021

Toxicity and efficacy of protracted low dose temozolomide for the treatment of low grade gliomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25035

7 January 2021

Temozolomide three weeks on and one week off as first line therapy for patients with recurrent or progressive low grade gliomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25035

7 January 2021

Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25035

7 January 2021

Temozolomide and cisplatin versus temozolomide in patients with advanced melanoma: a randomized phase II study of the Hellenic Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25035

7 January 2021

Cancer Research Campaign phase II trial of temozolomide in metastatic melanoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25035

7 January 2021

Temozolomide in combination with interferon-alfa versus temozolomide alone in patients with advanced metastatic melanoma: a randomized, phase III, multicenter study from the Dermatologic Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25035

7 January 2021

Temozolomide and whole brain irradiation in melanoma metastatic to the brain: a phase II trial of the Cytokine Working Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25035

7 January 2021

Phase II study of extended-dose temozolomide in patients with melanoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25035

7 January 2021

Correlation between O6-methylguanine-DNA methyltransferase and survival in inoperable newly diagnosed glioblastoma patients treated with neoadjuvant temozolomide

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25035

7 January 2021

Is protracted low-dose temozolomide feasible in glioma patients?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25035

7 January 2021

Pneumocystis pneumonia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25035

7 January 2021

Unexpected case of aplastic anemia in a patient with glioblastoma multiforme treated with Temozolomide.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25035

7 January 2021

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25035

7 January 2021

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25035

7 January 2021

Aplastic anaemia in patient with glioblastoma multiforme treated with temozolomide.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25035

7 January 2021

Non-Hodgkin's lymphoma in patients with glioma treated with temozolomide

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25035

7 January 2021

Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25035

7 January 2021

Treg depletion with a low-dose metronomic temozolomide regimen in a rat glioma model

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25035

7 January 2021

Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25035

7 January 2021

Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25035

7 January 2021

An increase in CD4+CD25+FOXP3+ regulatory T cells in tumor-infiltrating lymphocytes of human glioblastoma multiforme

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25035

7 January 2021

Leukocyte infiltration and tumor cell plasticity are parameters of aggressiveness in primary cutaneous melanoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25035

7 January 2021

Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25035

7 January 2021

Chemotherapy enhances vaccine-induced antitumor immunity in melanoma patients.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25035

7 January 2021

Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25035

7 January 2021

Identifiers

DOI

10.1002/CNCR.25035

1 reference

22 August 2017

1 reference